Brokerages Set Stryker Co. (NYSE:SYK) PT at $393.65

Shares of Stryker Co. (NYSE:SYK) have earned a consensus recommendation of “Moderate Buy” from the twenty ratings firms that are presently covering the company, MarketBeat reports. Four equities research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $393.65.

SYK has been the topic of several research analyst reports. Royal Bank of Canada increased their price target on shares of Stryker from $386.00 to $400.00 and gave the company an “outperform” rating in a report on Wednesday, October 30th. UBS Group lifted their price target on Stryker from $366.00 to $370.00 and gave the stock a “neutral” rating in a report on Wednesday, October 30th. BTIG Research upped their price objective on Stryker from $383.00 to $394.00 and gave the company a “buy” rating in a report on Wednesday, October 30th. Citigroup lifted their target price on Stryker from $406.00 to $411.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. Finally, Wolfe Research initiated coverage on shares of Stryker in a research note on Tuesday, September 10th. They issued an “outperform” rating and a $405.00 price target on the stock.

Stryker Price Performance

NYSE:SYK opened at $378.86 on Friday. The company has a quick ratio of 1.22, a current ratio of 1.91 and a debt-to-equity ratio of 0.66. Stryker has a 12-month low of $276.60 and a 12-month high of $381.54. The stock’s 50 day moving average price is $361.46 and its two-hundred day moving average price is $345.77. The firm has a market capitalization of $144.43 billion, a price-to-earnings ratio of 40.30, a P/E/G ratio of 2.83 and a beta of 0.91.

Stryker (NYSE:SYK) last released its quarterly earnings data on Tuesday, October 29th. The medical technology company reported $2.87 EPS for the quarter, topping analysts’ consensus estimates of $2.77 by $0.10. The firm had revenue of $5.49 billion during the quarter, compared to analysts’ expectations of $5.37 billion. Stryker had a net margin of 16.34% and a return on equity of 23.07%. The company’s revenue for the quarter was up 11.9% compared to the same quarter last year. During the same period in the previous year, the business posted $2.46 earnings per share. On average, analysts anticipate that Stryker will post 12.06 earnings per share for the current year.

Insider Buying and Selling

In other news, insider Viju Menon sold 600 shares of the firm’s stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $355.00, for a total value of $213,000.00. Following the sale, the insider now directly owns 9,069 shares in the company, valued at approximately $3,219,495. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other Stryker news, VP M Kathryn Fink sold 2,121 shares of the stock in a transaction dated Friday, September 13th. The stock was sold at an average price of $370.00, for a total value of $784,770.00. Following the completion of the transaction, the vice president now directly owns 10,042 shares in the company, valued at approximately $3,715,540. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Viju Menon sold 600 shares of the business’s stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $355.00, for a total value of $213,000.00. Following the sale, the insider now owns 9,069 shares in the company, valued at approximately $3,219,495. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 67,381 shares of company stock worth $24,825,275 in the last ninety days. 5.90% of the stock is owned by insiders.

Institutional Investors Weigh In On Stryker

Several hedge funds have recently added to or reduced their stakes in the business. Centennial Bank AR raised its stake in shares of Stryker by 106.7% during the second quarter. Centennial Bank AR now owns 93 shares of the medical technology company’s stock valued at $32,000 after acquiring an additional 48 shares during the last quarter. Darwin Wealth Management LLC acquired a new stake in Stryker in the third quarter valued at $36,000. Central Pacific Bank Trust Division bought a new position in Stryker during the 1st quarter worth $39,000. Hara Capital LLC acquired a new position in Stryker during the 3rd quarter worth about $42,000. Finally, HBW Advisory Services LLC bought a new stake in shares of Stryker in the 3rd quarter valued at about $42,000. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.